Monoamines and glycogen levels in cerebral cortices of fast and slow methionine sulfoximine-inbred mice

Epilepsy Research

Volumn 104, Issue 3, 2013, Pages 217-225

  Boissonnet, Arnaud ^a   Hévor, Tobias ^a   Landemarre, Ludovic ^b   Cloix, Jean François ^a  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b Glycodiag   (France)

Author keywords

Astrocytes; Glycogen; Methionine sulfoximine; Neurotransmitter; Seizure; Serotonin

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BRAIN MONOAMINE; GLUCOSE 6 PHOSPHATE; GLYCOGEN; METHIONINE SULFOXIMINE; NORADRENALIN; SEROTONIN;

ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; FLOW RATE; LATENT PERIOD; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SEIZURE; SEROTONINERGIC SYSTEM;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BIOGENIC MONOAMINES; BRAIN; DISEASE MODELS, ANIMAL; GLYCOGEN; HYDROXYINDOLEACETIC ACID; METHIONINE SULFOXIMINE; MICE; MICE, INBRED STRAINS; SEIZURES; SEROTONIN; THIOPHENES;

EID: 84876966098     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.11.007     Document Type: Article

References (46)

1. Abdelmalik P.A., Liang P., Weisspapir M., Samoilova M., Burnham W.M., Carlen P.L. Factors which abolish hypoglycemic seizures do not increase cerebral glycogen content in vitro. Neurobiol. Dis. 2008, 29:201-209.
2. Berlicki L. Inhibitors of glutamine synthetase and their potential application in medicine. Mini Rev. Med. Chem. 2008, 8:869-878.
3. Bernard-Hélary K., Ardourel M., Hévor T., Cloix J-F. In vivo and in vitro glycogenic effects of methionine sulfoximine are different in two inbred strains of mice. Brain Res. 2002, 929:147-155.
4. Bernard-Hélary K., Lapouble E., Ardourel M., Hevor T., Cloix J-F. Correlation between brain glycogen and convulsive state in mice submitted to methionine sulfoximine. Life Sci. 2000, 67:1773-1781.
5. Blizard D.A., Balkoski V. Tryptophan availability, central serotonergic function and methionine sulphoximine-induced convulsions. Neuropharmacology 1982, 21:27-30.
6. Blows W.T. Neurotransmitters of the brain: serotonin, noradrenaline (norepinephrine), and dopamine. J. Neurosci. Nurs. 2000, 32:234-238.
7. Boissonnet A., Hevor T., Cloix J.F. Phenotypic differences between Fast and Slow methionine sulfoximine-inbred mice: seizures, anxiety, and glutamine synthetase. Epilepsy Res. 2012, 98:25-34.
8. Chirita R.I., West C., Finaru A.L., Elfakir C. Approach to hydrophilic interaction chromatography column selection: application to neurotransmitters analysis. J. Chromatogr. A 2010, 1217:3091-3104.
9. Citraro R., Scicchitano F., De Fazio S., Raggio R., Mainardi P., Perucca E., De Sarro G., Russo E. Preclinical activity profile of alpha-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. Epilepsy Res. 2011, 95:60-69.
10. Cloix J.F., Ardourel M.Y., Hévor T. Glycogen metabolism and brain pathologies. Cent. Nerv. Syst. Agents Med. Chem 2008, 8:187-197.
11. Cloix J.F., Hevor T. Epilepsy, regulation of brain energy metabolism and neurotransmission. Curr. Med. Chem. 2009, 16:841-853.
12. Cloix J.F., Tahi Z., Boissonnet A., Hevor T. Brain glycogen and neurotransmitter levels in fast and slow methionine sulfoximine-selected mice. Exp. Neurol. 2010, 225:38-47.
13. Cloix J.F., Tahi Z., Martin B., Hevor T. Selection of two lines of mice based on latency to onset of methionine sulfoximine seizures. Epilepsia 2010, 51:118-128.
14. Dalsgaard M.K., Madsen F.F., Secher N.H., Laursen H., Quistorff B. High glycogen levels in the hippocampus of patients with epilepsy. J. Cereb. Blood Flow Metab. 2007, 27:1137-1141.
15. Dhir A. Novel discoveries in understanding the complexities of epilepsy and major depression. Expert Opin. Ther. Targets 2010, 14:109-115.
16. Eid T., Ghosh A., Wang Y., Beckstrom H., Zaveri H.P., Lee T.S., Lai J.C., Malthankar-Phatak G.H., de Lanerolle N.C. Recurrent seizures and brain pathology after inhibition of glutamine synthetase in the hippocampus in rats. Brain 2008, 131:2061-2070.
17. Eid T., Thomas M.J., Spencer D.D., Runden-Pran E., Lai J.C., Malthankar G.V., Kim J.H., Danbolt N.C., Ottersen O.P., de Lanerolle N.C. Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. Lancet 2004, 363:28-37.
18. Engel J., Brown W.J., Kuhl D.E., Phelps M.E., Mazziotta J.C., Crandall P.H. Pathological findings underlying focal temporal lobe hypometabolism in partial epilepsy. Ann. Neurol. 1982, 12:518-528.
19. Engel J., Kuhl D.E., Phelps M.E., Rausch R., Nuwer M. Local cerebral metabolism during partial seizures. Neurology 1983, 33:400-413.
20. Errichiello L., Pezzella M., Santulli L., Striano S., Zara F., Minetti C., Mainardi P., Striano P. A proof-of-concept trial of the whey protein alfa-lactalbumin in chronic cortical myoclonus. Mov. Disord. 2011, 26:2573-2575.
21. Folbergrova J. Glycogen and glycogen phosphorylase in the cerebral cortex of mice under the influence of methionine sulphoximine. J. Neurochem. 1973, 20:547-557.
22. Folbergrova J., Passonneau J.V., Lowry O.H., Schulz D.W. Glycogen, ammonia and related metabolites in the brain during seizures evoked by methionine sulphoximine. J. Neurochem. 1969, 16:191-203.
23. Fonnum F., Paulsen R.E. Comparison of transmitter amino acid levels in rat globus pallidus and neostriatum during hypoglycemia or after treatment with methionine sulfoximine or gamma-vinyl gamma-aminobutyric acid. J. Neurochem. 1990, 54:1253-1257.
24. Hevor T. Methionine sulfoximine has no effect on gamma aminobutyric acid concentration in the brain. Biog. Amines 1996, 12:445-461.
25. Hevor T., Richard O., Pichon J., Hélary K., Cloix J.F. Acetylcholine, catecholamine, indoleamine, and GABA levels in the brain of rats submitted to a convulsant. Neurochemical markers of degenerative nervous diseases and drug addiction. Progress in HPLC-HPCE 1998, vol. 7:383-411. VSP Zest, The Netherlands.
26. Hevor T.K., Aissi E., Delorme P. Correlation between carbohydrate and catecholamine level impairments in methionine sulfoximine epileptogenic rat brain. Neurochem. Res. 1990, 15:861-868.
27. Hevor T.K., Delorme P. Possible involvement of indolamines in the glycogenic effect of the convulsant methionine sulfoximine in rat brain. Experientia 1990, 46:710-713.
28. Jabs R., Seifert G., Steinhauser C. Astrocytic function and its alteration in the epileptic brain. Epilepsia 2008, 49(Suppl. 2):3-12.
29. King J.T., LaMotte C.C. El mouse as a model of focal epilepsy: a review. Epilepsia 1989, 30:257-265.
30. Lai V., Mak H.K., Yung A.W., Ho W.Y., Hung K.N. Neuroimaging techniques in epilepsy. Hong Kong Med. J. 2010, 16:292-298.
31. Liew C.J., Lim Y.M., Bonwetsch R., Shamim S., Sato S., Reeves-Tyer P., Herscovitch P., Dustin I., Bagic A., Giovacchini G., Theodore W.H. 18F-FCWAY and 18F-FDG PET in MRI-negative temporal lobe epilepsy. Epilepsia 2009, 50:234-239.
32. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
33. Margineanu D.G. Epileptic hypersynchrony revisited. Neuroreport 2010, 21:963-967.
34. Mefford I.N. Application of high performance liquid chromatography with electrochemical detection to neurochemical analysis: measurement of catecholamines, serotonin and metabolites in rat brain. J. Neurosci. Methods 1981, 3:207-224.
35. Meister A. Inhibition of glutamine synthase and gamma glutamylcysteine synthetase by methionine sulfoximine and related compounds. Enzyme Activated Irreversible Inhibitiors 1978, 187-210. Elsevier, Amsterdam, The Netherlands. N. Seiler, M.J. Jung, J. Koch-Weser (Eds.).
36. Respaud R., Tournamille J.F., Croix C., Laborie H., Elfakir C., Viaud-Massuard M.C. Development of an ion-pairing reversed-phase liquid chromatography method using a double detection analysis (UV and evaporative light scattering detection) to monitor the stability of Alimta((R))-pemetrexed preparations: identification and quantification of l-glutamic acid as a potential degradation product. J. Pharm. Biomed. Anal. 2011, 54:411-416.
37. Samuels S., Fish I., Freedman L.S. Effect of gamma-glutamyl cycle inhibitors on brain amino acid transport and utilization. Neurochem. Res. 1978, 3:619-631.
38. Schank J.R., Liles L.C., Weinshenker D. Reduced anticonvulsant efficacy of valproic acid in dopamine beta-hydroxylase knockout mice. Epilepsy Res. 2005, 65:23-31.
39. Serratosa, J.M., Minassian, B.A., Ganesh, S., 2012. Progressive Myoclonus Epilepsy of Lafora.
40. Sitoh Y.Y., Tien R.D. Neuroimaging in epilepsy. J. Magn. Reson. Imaging 1998, 8:277-288.
41. Trindade-Filho E.M., de Castro-Neto E.F., de A.C.R., Lima E., Scorza F.A., Amado D., Naffah-Mazzacoratti Mda G., Cavalheiro E.A. Serotonin depletion effects on the pilocarpine model of epilepsy. Epilepsy Res. 2008, 82:194-199.
42. Turnbull J., Wang P., Girard J.M., Ruggieri A., Wang T.J., Draginov A.G., Kameka A.P., Pencea N., Zhao X., Ackerley C.A., Minassian B.A. Glycogen hyperphosphorylation underlies lafora body formation. Ann. Neurol. 2010, 68:925-933.
43. Valles-Ortega J., Duran J., Garcia-Rocha M., Bosch C., Saez I., Pujadas L., Serafin A., Canas X., Soriano E., Delgado-Garcia J.M., Gruart A., Guinovart J.J. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease. EMBO Mol. Med. 2011, 3:667-681.
44. Vilchez D., Ros S., Cifuentes D., Pujadas L., Valles J., Garcia-Fojeda B., Criado-Garcia O., Fernandez-Sanchez E., Medrano-Fernandez I., Dominguez J., Garcia-Rocha M., Soriano E., Rodriguez de Cordoba S., Guinovart J.J. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat. Neurosci. 2007, 10:1407-1413.
45. Wilson S.J., Engel J. Diverse perspectives on developments in epilepsy surgery. Seizure 2010, 19:659-668.
46. Wolfe L.S., Elliot K.A.C. Chemical studies in regulation to convulsive conditions. Neurochemistry 1962, 694-697. Springfield, USA. second ed. K.A.C. Elliot, I.H. Page, J.H. Quastel (Eds.).